27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Over half of men who receive treatment for prostate suffer from a range of sexual problems that affect negatively their sexual health, sexual intimacy with their partners and their quality of life. In clinical practice, however, care for the sexual side effects of treatment is often suboptimal or unavailable. The goal of the current study is to test a web-based intervention to support the recovery of sexual intimacy of prostate cancer survivors and their partners after treatment.

          Methods

          The study team developed an interactive, web-based intervention, tailored to type of treatment received, relationship status (partnered/non-partnered) and sexual orientation. It consists of 10 modules, six follow the trajectory of the illness and four are theme based. They address sexual side effects, rehabilitation, psychological impacts and coaching for self-efficacy.

          Each includes a video to engage participants, psychoeducation and activities completed by participants on the web. Tailored strategies for identified concerns are sent by email after each module. Six of these modules will be tested in a randomized controlled trial and compared to usual care. Men with localized prostate cancer with partners will be recruited from five academic medical centers. These couples ( N = 140) will be assessed prior to treatment, then 3 months and 6 months after treatment. The primary outcome will be the survivors’ and partners’ Global Satisfaction with Sex Life, assessed by a Patient Reported Outcome Measure Information Systems (PROMIS) measure. Secondary outcomes will include interest in sex, sexual activity, use of sexual aids, dyadic coping, knowledge about sexual recovery, grief about the loss of sexual function, and quality of life. The impact of the intervention on the couple will be assessed using the Actor-Partner Interaction Model, a mixed-effects linear regression model able to estimate both the association of partner characteristics with partner and patient outcomes and the association of patient characteristics with both outcomes.

          Discussion

          The web-based tool represents a novel approach to addressing the sexual health needs of prostate cancer survivors and their partners that—if found efficacious—will improve access to much needed specialty care in prostate cancer survivorship.

          Trial registration

          Clinicaltrials.gov registration # NCT02702453, registered on March 3, 2016.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Marital status and survival in patients with cancer.

          To examine the impact of marital status on stage at diagnosis, use of definitive therapy, and cancer-specific mortality among each of the 10 leading causes of cancer-related death in the United States.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

            Health-related quality of life (HRQOL) is an increasingly important endpoint in prostate cancer care. However, pivotal issues that are not fully assessed in existing HRQOL instruments include irritative urinary symptoms, hormonal symptoms, and multi-item scores quantifying bother between urinary, sexual, bowel, and hormonal domains. We sought to develop a novel instrument to facilitate more comprehensive assessment of prostate cancer-related HRQOL. Instrument development was based on advice from an expert panel and prostate cancer patients, which led to expanding the 20-item University of California-Los Angeles Prostate Cancer Index (UCLA-PCI) to the 50-item Expanded Prostate Index Composite (EPIC). Summary and subscale scores were derived by content and factor analyses. Reliability and validity were assessed by test-retest correlation, Cronbach's alpha coefficient, interscale correlation, and EPIC correlation with other validated instruments. Test-retest reliability and internal consistency were high for EPIC urinary, bowel, sexual, and hormonal domain summary scores (each r >/=0.80 and Cronbach's alpha >/=0.82) and for most domain-specific subscales. Correlations between function and bother subscales within domains were high (r >0.60). Correlations between different primary domains were consistently lower, indicating that these domains assess distinct HRQOL components. EPIC domains had weak to modest correlations with the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12), indicating rationale for their concurrent use. Moderate agreement was observed between EPIC domains relevant to the Functional Assessment of Cancer Therapy Prostate module (FACT-P) and the American Urological Association Symptom Index (AUA-SI), providing criterion validity without excessive overlap. EPIC is a robust prostate cancer HRQOL instrument that complements prior instruments by measuring a broad spectrum of urinary, bowel, sexual, and hormonal symptoms, thereby providing a unique tool for comprehensive assessment of HRQOL issues important in contemporary prostate cancer management.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Demographics of the gay and lesbian population in the United States: evidence from available systematic data sources.

              This work provides an overview of standard social science data sources that now allow some systematic study of the gay and lesbian population in the United States. For each data source, we consider how sexual orientation can be defined, and we note the potential sample sizes. We give special attention to the important problem of measurement error, especially the extent to which individuals recorded as gay and lesbian are indeed recorded correctly. Our concern is that because gays and lesbians constitute a relatively small fraction of the population, modest measurement problems could lead to serious errors in inference. In examining gays and lesbians in multiple data sets we also achieve a second objective: We provide a set of statistics about this population that is relevant to several current policy debates.
                Bookmark

                Author and article information

                Contributors
                734.615.2878 , dwittman@med.umich.edu
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                2 October 2017
                2 October 2017
                2017
                : 17
                : 664
                Affiliations
                [1 ]ISNI 0000000086837370, GRID grid.214458.e, University of Michigan, ; 2800 Plymouth Road, Bldg. 16, Rm 110E, Ann Arbor, MI 48109-2800 USA
                [2 ]ISNI 0000 0001 0941 6502, GRID grid.189967.8, Emory University, ; Atlanta, GA USA
                [3 ]University of California-Los Angeles, California, Los Angeles USA
                [4 ]ISNI 000000041936754X, GRID grid.38142.3c, Dana Farber Cancer Center and Harvard University, ; Boston, MA USA
                [5 ]ISNI 0000 0001 1034 1720, GRID grid.410711.2, University of North Carolina, ; Chapel Hill, NC USA
                [6 ]ISNI 0000000107903411, GRID grid.241116.1, University of Colorado-Denver, ; Denver, CO USA
                [7 ]ISNI 0000 0001 2297 6811, GRID grid.266102.1, University of California-San Francisco, ; San Francisco, CA USA
                [8 ]ISNI 0000 0004 1936 7961, GRID grid.26009.3d, Duke University, ; Durham, NC USA
                [9 ]Prostate Cancer Foundation-Australia, St Leonards, Australia
                [10 ]ISNI 0000 0001 2171 9952, GRID grid.51462.34, Memorial Sloan Kettering Cancer Center, ; New York City, NY USA
                [11 ]TrueNTH Movember Foundation, Michigan, USA
                [12 ]Fred Hutchinson Comprehensive Cancer Center, Seattle, Washington USA
                [13 ]ISNI 0000000122986657, GRID grid.34477.33, University of Washington, ; Seattle, Washington USA
                [14 ]ISNI 0000 0001 2171 9311, GRID grid.21107.35, Johns Hopkins University, ; Baltimore, MD USA
                [15 ]ISNI 0000 0004 0419 7525, GRID grid.413800.e, VA Ann Arbor Healthcare System, HSRD Center for Clinical Management Research, ; Ann Arbor, USA
                Article
                3652
                10.1186/s12885-017-3652-3
                5625773
                28969611
                2932ae6b-e3dc-4f8a-9cf7-f9c5b3300a30
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 28 November 2016
                : 22 September 2017
                Funding
                Funded by: Movember Foundation (AU)
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2017

                Oncology & Radiotherapy
                prostate cancer sexual recovery cancer survivorship intervention

                Comments

                Comment on this article